Lirilumab
Lirilumab
Lirilumab (pronounced: li-ri-lu-mab) is a type of immunotherapy drug that is currently under investigation for the treatment of various types of cancer. It is a monoclonal antibody that targets the Killer-cell immunoglobulin-like receptor (KIR) on natural killer cells to enhance the body's immune response against cancer cells.
Etymology
The name "Lirilumab" follows the International Nonproprietary Name (INN) guidelines for naming monoclonal antibodies. The prefix "Liri-" is arbitrary, the infix "-lu-" indicates the drug's role in immunomodulation, and the suffix "-mab" denotes that the drug is a monoclonal antibody.
Mechanism of Action
Lirilumab works by binding to the KIR receptors on natural killer cells. These receptors usually inhibit the activity of natural killer cells when they bind to certain proteins on the surface of normal cells. By blocking these receptors, Lirilumab allows the natural killer cells to remain active and destroy cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
- Killer-cell immunoglobulin-like receptor (KIR): A type of receptor found on the surface of natural killer cells that helps to regulate their activity.
- Natural killer cell: A type of immune cell that has the ability to kill certain cells, including cancer cells and virus-infected cells.
External links
- Medical encyclopedia article on Lirilumab
- Wikipedia's article - Lirilumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski